Sanofi abruptly halted development of Nurix Therapeutics’ oral STAT6 degrader SAR448272 (NX-3911), dealing a direct blow to the companies’ multi-year immunology/protein-degradation collaboration. Nurix disclosed the termination as part of its latest StockWatch coverage, noting the Phase 1 first-in-human program had been recruiting in Europe. Nurix had already received a $10 million milestone payment tied to expansion progress and, as of Aug. 31, reported $129 million paid under the collaboration structure. The companies said the broader research partnership continues, but investors reacted negatively to the discontinued program. The termination matters for Nurix’s near- to mid-term clinical portfolio composition and for Sanofi’s STAT6 pipeline strategy in type 2 inflammation, where targeted degradation had been positioned as a mechanism-expanding approach. Nurix maintained that its cash runway would not be materially impacted, but the stock sold off sharply after market closure, underscoring how single-program deletions can quickly change perceived risk in protein-degradation platforms.